Phil has over 20 years’ experience in biopharmaceutical R&D and has held senior operational and leadership roles in the development of novel antibody therapeutics. He began his career at the Glaxo Institute of Applied Pharmacology and GlaxoWellcome before gaining biologics expertise at Cambridge Antibody Technology (CAT) and PanGenetics. Phil has also held CSO positions in smaller venture-backed companies focused on the discovery and development of antibody therapeutics (Navion and SweetSpot Therapeutics) and was a co-founder at Nascient.
Prior to joining Crescendo, Phil was a VP at Kymab with particular responsibility for the scientific leadership of their most advanced development programme.
Phil holds a BPharm degree in pharmacy and a PhD in pharmacology, both from King’s College London.